StreetAlpha.app
Home › Stocks › CAPR

Capricor Therapeutics, Inc. (CAPR)

Healthcare
$8.41
▲ +1.33%
LAST CLOSE · NOV 17

Capricor Therapeutics is a San Diego biotechnology company developing a cell therapy for Duchenne muscular dystrophy. It last closed at $8.41 on Nov 17, up 1.33% on the day. CAPR last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 4 analysts is $20.38 (+142.3% from the last close), with a high of $25.00 and a low of $10.50. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CAPR, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print totaling $250K, the largest $250K.

AI Auto Pilots
Is CAPR in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$105.0M
EPS (diluted)
−$2.26
Free cash flow
−$72.7M
Valuation
Market cap
$489.0M
58.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$44.3M
At Sep 30
Shareholder equity
$209.8M
Shares outstanding
58.1M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $245K$245KFY2021FY2022: $2.6M$2.6MFY2022FY2023: $25.2M$25.2MFY2023FY2024: $22.3M$22.3MFY2024FY2025: $0$0FY2025

From CAPR's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 10).

Last report
Nov 10
2026 · After the close (AMC)
Reported EPS
-$0.73
vs -$0.61 est. · miss
Year-ago EPS
-$0.54
Same quarter last year
Options-implied move
±33.1%
Priced in before that report
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on CAPR in the past 90 days
Average 12-month target
$20.38
▲ 142.3% upside

Based on 4 analysts who set a price target on CAPR in the past 90 days. The average target is $20.38, with a high of $25.00 and a low of $10.50, compared with the last close of $8.41.

$2$11$20$28PAST 46 TRADING DAYS12-MONTH TARGETSHIGH $25AVG $20.38LOW $10.50Jun 26LAST CLOSE+12 MO$2$11$20$28PAST 46 DAYSTARGETSHIGH $25AVG $20.38LOW $10.50Jun 26LAST CLOSE+12 MO
Highest target$25.00
Average target$20.38
Lowest target$10.50
Latest rating changes
Roth CapitalReiterated
Nov 13Hold$10.50
Jones TradingUpgrade
Nov 11Buy$25
B. Riley SecuritiesUpgrade
Sep 14Buy$21
Piper SandlerUpgrade
Sep 1Buy$2 → $25
Cantor FitzgeraldUpgrade
Aug 14Buy$3.50 → $28
DateFirmActionRatingPrice target
Nov 13Roth CapitalReiteratedHold$10.50
Nov 11Jones TradingUpgradeBuy$25
Sep 14B. Riley SecuritiesUpgradeBuy$21
Sep 1Piper SandlerUpgradeBuy$2 → $25
Aug 14Cantor FitzgeraldUpgradeBuy$3.50 → $28
Loading…

Technical Analysis

CAPR · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 6% above its 20 day and 4% above its 50 day average. It is 136% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the swing low (Sep 10) at $8.18, and the nearest resistance the Pivot at $8.53.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 11.5%/day
Key levels
$40.3752 week high+380.0%
$19.81200 day average+135.6%
$10.15100 day average+20.7%
$9.79Swing high (Sep 17)+16.4%
$8.86Pivot R1+5.4%
$8.53Pivot+1.4%
$8.41Last close
$8.18Swing low (Sep 10)−2.7%
$8.09Pivot S1−3.8%
$8.0750 day average−4.0%
$7.8720 day average−6.4%
$2.9652 week low−64.8%
Indicators
RSI (14)50.65Middle of its rangeNeutral
MACD0.47Above its signal lineBullish
Stochastic53.0Middle of its rangeNeutral
ADX (14)29.1Trending up
Williams %R-55.4Oversold below −80, overbought above −20Neutral
CCI (20)33.6Oversold below −100, overbought above 100Neutral
Rate of change+2.1%Change over 10 sessionsBullish
ATR (14)$0.97Typical daily range, 11.5% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for CAPR

What happened before

See how CAPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CAPR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CAPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 7 – Oct 7
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$250K
Largest print
$250K
Loading…

CAPR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●93 buying vs 86 selling
  • ▲Held by funds +1.8 pts
  • ▼Funds holding -12
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158170−7.1%
In funds' top 1003−100.0%
Held by funds69.3%67.6%+1.8 pts
New / increased35 / 5826 / 71−4.1%
Reduced / sold out39 / 4745 / 35+7.5%
Put/call ratio0.660.46+43.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CAPR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAPR is in one of them and how their past CAPR trades turned out.

CAPR in the AI portfolios
Loading…

CAPR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CAPR in an article yet. Here's the latest on the wider market.

CAPR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 6
Who traded CAPR · since 2017
Latest 2 filings
$1K – $15KTraded Jul 27, 2017Filed Aug 6, 2018
$1K – $15KTraded Jul 27, 2017Filed Aug 6, 2018
PersonTypeAmountTradedFiledDelay
Roger MarshallR · KSSell$1K – $15KJul 27, 2017Aug 6, 2018375 d
Roger MarshallR · KSBuy$1K – $15KJul 27, 2017Aug 6, 2018375 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company based in San Diego, California. It is developing Deramiocel, a cell therapy for Duchenne muscular dystrophy, a rare genetic disease that causes progressive muscle loss and weakness. The company is also studying a platform built on exosomes, which are small vesicles released by cells, for other possible diseases. It has no approved products yet, and its target patients are people living with this condition.

Headquarters
San Diego, CA